NO20070831L - Middel for aktivering av tilfriskning fra dysfunksjon etter starten av sentralnevrologisk sykdom. - Google Patents
Middel for aktivering av tilfriskning fra dysfunksjon etter starten av sentralnevrologisk sykdom.Info
- Publication number
- NO20070831L NO20070831L NO20070831A NO20070831A NO20070831L NO 20070831 L NO20070831 L NO 20070831L NO 20070831 A NO20070831 A NO 20070831A NO 20070831 A NO20070831 A NO 20070831A NO 20070831 L NO20070831 L NO 20070831L
- Authority
- NO
- Norway
- Prior art keywords
- activating
- onset
- neurological disease
- recovery
- dysfunction
- Prior art date
Links
- 230000003213 activating effect Effects 0.000 title abstract 7
- 238000011084 recovery Methods 0.000 title abstract 7
- 208000012902 Nervous system disease Diseases 0.000 title abstract 5
- 208000025966 Neurological disease Diseases 0.000 title abstract 5
- 230000004064 dysfunction Effects 0.000 title abstract 4
- 230000000694 effects Effects 0.000 abstract 5
- 239000003795 chemical substances by application Substances 0.000 abstract 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 abstract 4
- 230000005062 synaptic transmission Effects 0.000 abstract 4
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 229960002748 norepinephrine Drugs 0.000 abstract 2
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 abstract 2
- 229940076279 serotonin Drugs 0.000 abstract 2
- 230000001078 anti-cholinergic effect Effects 0.000 abstract 1
- 206010013663 drug dependence Diseases 0.000 abstract 1
- 208000011117 substance-related disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2004207234 | 2004-07-14 | ||
| PCT/JP2005/012895 WO2006006617A1 (ja) | 2004-07-14 | 2005-07-13 | 中枢神経疾患発症後の機能障害の回復促進剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20070831L true NO20070831L (no) | 2007-02-13 |
Family
ID=35783954
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20070831A NO20070831L (no) | 2004-07-14 | 2007-02-13 | Middel for aktivering av tilfriskning fra dysfunksjon etter starten av sentralnevrologisk sykdom. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20070259865A1 (ja) |
| EP (1) | EP1767217A1 (ja) |
| JP (1) | JPWO2006006617A1 (ja) |
| CN (1) | CN1984681A (ja) |
| AU (1) | AU2005260955A1 (ja) |
| BR (1) | BRPI0513222A (ja) |
| CA (1) | CA2573611A1 (ja) |
| IL (1) | IL180379A0 (ja) |
| NO (1) | NO20070831L (ja) |
| RU (1) | RU2007105494A (ja) |
| WO (1) | WO2006006617A1 (ja) |
| ZA (1) | ZA200700711B (ja) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101213211A (zh) | 2005-06-17 | 2008-07-02 | 惠氏公司 | 纯化含Fc区蛋白的方法 |
| TW200846002A (en) * | 2007-03-15 | 2008-12-01 | Astellas Pharma Inc | Novel prophylactic and/or therapeutic agent for diabetic neuropathy |
| TW200846003A (en) * | 2007-03-15 | 2008-12-01 | Astellas Pharma Inc | Novel prophylactic and/or therapeutic agent for diabetic neuropathy |
| DE102007051090A1 (de) * | 2007-06-28 | 2009-01-08 | Charité - Universitätsmedizin Berlin | SSRI zur Behandlung neuronaler Krankheiten |
| US8153813B2 (en) * | 2007-12-20 | 2012-04-10 | Abbott Laboratories | Benzothiazole and benzooxazole derivatives and methods of use |
| FR2978350B1 (fr) | 2011-07-28 | 2013-11-08 | Pf Medicament | Medicament a base de levomilnacipran pour la rehabilitation fonctionnelle apres accident neurologique aigu |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE187448T1 (de) * | 1993-02-10 | 1999-12-15 | Yamanouchi Pharma Co Ltd | Morpholinderivate |
| MXPA05004381A (es) * | 2002-10-25 | 2006-02-10 | Collegium Pharmaceutical Inc | Estereoisomeros de para-hidroxi-milnacipran y metodos de uso de los mismos. |
-
2005
- 2005-07-13 EP EP05765630A patent/EP1767217A1/en not_active Withdrawn
- 2005-07-13 WO PCT/JP2005/012895 patent/WO2006006617A1/ja not_active Ceased
- 2005-07-13 RU RU2007105494/15A patent/RU2007105494A/ru unknown
- 2005-07-13 BR BRPI0513222-3A patent/BRPI0513222A/pt not_active Application Discontinuation
- 2005-07-13 US US11/631,782 patent/US20070259865A1/en not_active Abandoned
- 2005-07-13 AU AU2005260955A patent/AU2005260955A1/en not_active Abandoned
- 2005-07-13 CA CA002573611A patent/CA2573611A1/en not_active Abandoned
- 2005-07-13 JP JP2006529080A patent/JPWO2006006617A1/ja not_active Withdrawn
- 2005-07-13 CN CNA2005800236634A patent/CN1984681A/zh active Pending
- 2005-07-13 ZA ZA200700711A patent/ZA200700711B/en unknown
-
2006
- 2006-12-27 IL IL180379A patent/IL180379A0/en unknown
-
2007
- 2007-02-13 NO NO20070831A patent/NO20070831L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| ZA200700711B (en) | 2008-07-30 |
| CN1984681A (zh) | 2007-06-20 |
| EP1767217A1 (en) | 2007-03-28 |
| AU2005260955A1 (en) | 2006-01-19 |
| US20070259865A1 (en) | 2007-11-08 |
| RU2007105494A (ru) | 2008-09-10 |
| BRPI0513222A (pt) | 2008-04-29 |
| IL180379A0 (en) | 2007-06-03 |
| JPWO2006006617A1 (ja) | 2008-04-24 |
| WO2006006617A1 (ja) | 2006-01-19 |
| CA2573611A1 (en) | 2006-01-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2007002356A1 (es) | Sistema de liberacion farmaceutica que comprende flibanserina y por lo menos un excipiente farmaceuticamentre aceptable; y su uso para el tratamiento de trastornos del sistema nervioso central, trastornos afectivos, del sueno y sexuales, entre otros. | |
| NO20070831L (no) | Middel for aktivering av tilfriskning fra dysfunksjon etter starten av sentralnevrologisk sykdom. | |
| NO2012017I1 (no) | Benzimidazolderivat, fremgangsmåte for fremstilling derav, medikament inneholdende denne forbindelsen samt anvendelse av forbindelsen. | |
| CL2004000643A1 (es) | Composicion farmaceutica que comprende un agonista de 5-ht 1b/1d y un inhibidor selectivo de ciclooxigenasa-2, util en el tratamiento de la migrana. | |
| CL2007001918A1 (es) | Compuestos derivados heteroarilos sustituidos; metodo para la preparacion de los compuestos; composicion farmaceutica; y uso para el tratamiento del dolor, depresion, enfermedad de alzheimer e hipertension entre otras. | |
| NO20061074L (no) | Forbindelser og sammensetninger som inbibitorer av reseptortyrosinkinaseaktivitet | |
| NO20060871L (no) | Azepinderivater som farmasoytiske midler | |
| CL2007003352A1 (es) | Compuestos derivados de heteromonociclos de nitrogeno; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de enfermedades circulatorias, enfermedades metabolicas y/o enfermedades del sistema nervioso cen | |
| NO20070578L (no) | Oral doseringsform sikret mot misbruk inneholdende (1,2R)-3-(3-dimetylammino-l-etyl-2-metyl-propyl)-fenol | |
| ITMI20041317A1 (it) | Formulazioni farmaceutiche per la somministrazione sicura di farmaci utilizzati nel trattamento della tossicodipendenza e procedimento per il loro ottenimento | |
| NO20070046L (no) | Nytt cykloheksanderivat, prodrug derav og salt derav, og terapeutisk middel inneholdende de samme for diabetes | |
| NO20052496D0 (no) | Selekterte CGRP antagonister, fremgangsmater for fremstilling derav og anvendelse derav som medikamenter. | |
| AR047841A1 (es) | Metodos y composiciones para el tratamiento de transtornos inmunoinflamatorios | |
| AR059359A1 (es) | Formulaciones farmaceuticas que contienen pleconaril | |
| MY145074A (en) | Thiazolidin-4-one derivatives | |
| EP1933785A4 (en) | COMPOSITIONS, SYSTEMS, KITS AND METHODS FOR THE ADMINISTRATION OF RAPAMYCIN ANALOGUE WITH PACLITAXEL USING MEDICAL DEVICES | |
| AR059357A1 (es) | Formulaciones farmaceuticas | |
| UY27188A1 (es) | Uso de agonistas inversos de gabaa en combinación con agonistas parciales del receptor de nicotina, estrógenos, moduladores selectivos de estrógenos o vitamina e, para el tratamiento de trastornos cognitivos. | |
| DK1614419T3 (da) | Midler til forebyggelse/behandling af retinale nervesygdomme, indeholdende alkyletherderivater eller salte deraf | |
| NO20092763L (no) | Isosorbid mononitrat derivater for behandling av tarmlidelser | |
| AR055628A1 (es) | Dipositivos de administracion transdermicas de farmacos que contienen o- desmetilvenlafaxina (odv) o sus sales | |
| UY29108A1 (es) | Ligandos de difenil éter terapéuticos | |
| NO20061702L (no) | Farmasoytiske sammensetninger og fremgangsmater omfattende kombinasjoner av 2-alkyliden-19-nor-vitamin D derivater og en ostrogen agonist/antagonist | |
| ECSP109871A (es) | Soluciones farmacéuticas orales que contienen telbivudina | |
| NO20064808L (no) | Orale matrixformuleringer med licarbazepin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |